                         SEQUENCE LISTING

<110>  SerEye GmbH
 
<120>  Composition for treating eye diseases and method of producing 
       same

<130>  SY18A04/P-WO

<150>  EP 20 189 111.6
<151>  2020-08-03

<160>  6     

<170>  PatentIn version 3.5

<210>  1
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer MMP-9 forward

<400>  1
agtaccgaag agaaagccta ctt                                               23


<210>  2
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer MMP-9 reverse

<400>  2
tgcaggatgt caaagctcac                                                   20


<210>  3
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer GAPDH forward

<400>  3
gaaggtgaag gtcggagt                                                     18


<210>  4
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer GAPDH reverse

<400>  4
gaagatggtg atgggatttc                                                   20


<210>  5
<211>  19
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer beta-actin forward

<400>  5
gctatttggc dctggactt                                                    19


<210>  6
<211>  19
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer beta-actin reverse

<400>  6
gcggctcgta gctcttctc                                                    19


